Former CEO, Cambridge Antibody Technology (CAT), Nabriva Therapeutics and Kymab; Currently Chairman, Epsilogen and Board Member of Avillion Bond 2 Development 2 GP

President and CEO, Mass General Brigham; Laurie Carrol Guthart Professor of Medicine, Harvard Medical School

Chief Business Officer and Chief Financial Officer, Entasis Therapeutics

Former President and co-CEO, United Therapeutics

Former Senior Vice President, Head of North America, Rare Diseases, Genzyme, a Sanofi Company

Former CFO, Tom’s of Maine; Board of Trustees, Allianz Global Investors

President and Chief Executive Officer